A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02682927 |
|
Recruitment Status :
Active, not recruiting
First Posted : February 17, 2016
Last Update Posted : January 7, 2020
|
Sponsor:
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Information provided by (Responsible Party):
Zogenix, Inc. ( Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a multicenter, double-blind, parallel-group, placebo-controlled, study to assess the efficacy, safety, and PK of ZX008 when used as adjunctive therapy for uncontrolled seizures in pediatric and young adult subjects with Dravet syndrome. After an initial Screening and Baseline charting of seizure frequency, subjects who qualify for the study will be randomized (1:1:1) to receive either ZX008 (0.2 mg/kg/day, 0.8 mg/kg/day; maximum dose: 30 mg/day) or placebo. Randomization will be stratified by age group (< 6 years, ≥6 to 18 years). All subjects will be titrated to their randomized dose over a 14-day Titration Period. Following titration, subjects will continue treatment at their randomly assigned dose over a 12-week Maintenance Period. Subjects exiting the study will undergo a 2-week taper, unless they enroll in a follow-on study. Subjects will be followed for post-study safety monitoring. Parents/caregivers will use a diary daily to record the number/type of seizures, dosing, and use of rescue medication.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Dravet Syndrome Seizure Disorder | Drug: ZX008 (Fenfluramine Hydrochloride) Drug: Matching Placebo | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 130 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome |
| Study Start Date : | January 2016 |
| Estimated Primary Completion Date : | July 2020 |
| Estimated Study Completion Date : | July 2020 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Pyridoxal 5'-phosphate-dependent epilepsy
CDKL5 deficiency disorder
Genetic epilepsy with febrile seizures plus
MedlinePlus related topics:
Seizures
| Arm | Intervention/treatment |
|---|---|
|
Experimental: ZX008 - 0.8 mg/kg/day
ZX008 (fenfluramine HCl) is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.
|
Drug: ZX008 (Fenfluramine Hydrochloride)
ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5. The product is sugar free and is intended to be compatible with a ketogenic diet. |
|
Experimental: ZX008 - 0.2 mg/kg/day
ZX008 (fenfluramine HCl) is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.
|
Drug: ZX008 (Fenfluramine Hydrochloride)
ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5. The product is sugar free and is intended to be compatible with a ketogenic diet. |
|
Placebo Comparator: Matching Placebo
Placebo will be administered twice a day (BID) in equally divided doses with food.
|
Drug: Matching Placebo
Placebo solution for ZX008. The product is sugar free and is intended to be compatible with a ketogenic diet. |
Primary Outcome Measures :
- Change in mean convulsive seizure frequency comparing the baseline with the combined titration and maintenance period for ZX008 0.8mg/kg/day group compared with placebo group. [ Time Frame: 0-14 weeks ]
Secondary Outcome Measures :
- Proportion of subjects in each ZX008 treatment arm compared with placebo who were considered treatment responders, defined as those with a ≥40% and ≥50%, reduction in convulsive seizures from baseline. [ Time Frame: 0-14 weeks ]
- Comparison of subjects' longest seizure-free interval in each ZX008 treatment arm compared with placebo [ Time Frame: 0-14 weeks ]Comparison of each subjects' longest convulsive seizure-free interval, and longest interval without any seizures, during the 14-week titration + maintenance period, will be calculated independently for the ZX008 0.8 and 0.2 mg/kg/day treatment groups versus placebo from seizure diary records.
- Additional secondary outcome measures [ Time Frame: Baseline compared with Titration + Maintenance period, or T+M as appropriate ]
- The number of convulsive seizure-free days
- The proportion of subjects who achieve ≥75% reductions from baseline in convulsive seizure frequency
- The change from baseline in non-convulsive seizure frequency and all seizure frequency
- The incidence of rescue medication usage, and medical utilization
- The incidence of status epilepticus
- Clinical Global Impression - Improvement rating, as assessed by the parent/caregiver
- The change from baseline in Quality of Life
- The change from baseline in affective symptoms of the parent/caregiver
- Safety and tolerability of ZX008 0.2 and 0.8 mg/kg/day compared to placebo [ Time Frame: baseline through study endpoint ]Compare safety and tolerability of ZX008 0.2 and 0.8 mg/kg/day and placebo with regard to adverse events (AEs), laboratory parameters, physical examination, neurological examination, vital signs (blood pressure, heart rate, temperature, and respiratory rate), electrocardiograms (ECG), echocardiograms (ECHO), body weight and cognitive function.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 2 Years to 18 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Key Inclusion Criteria:
- Male or non-pregnant, non-lactating female, age 2 to 18 years, inclusive as of the day of the Screening Visit.
- Clinical diagnosis of Dravet syndrome, where convulsive seizures are not completely controlled by current antiepileptic drugs.
- Must have a minimum # of convulsive seizures per 4-week period for past 12 weeks prior to screening
- All medications or interventions for epilepsy must be stable for at least 4 weeks prior to screening and expected to remain stable throughout the study.
- No cardiovascular or cardiopulmonary abnormality based on ECHO, ECG or physical examination
- Parent/caregiver is willing and able to be compliant with diary completion, visit schedule and study drug accountability.
Key Exclusion Criteria:
- Pulmonary arterial hypertension.
- Current or past history of cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, myocardial infarction or stroke.
- Current or past history of glaucoma.
- Moderate or severe hepatic impairment.
- Receiving concomitant therapy with: anorectic agents; monoamine-oxidase inhibitors; medications that act via serotonin including serotonin reuptake inhibitors; atomoxetine, or other centrally-acting noradrenergic agonist; or cyproheptadine.
- Currently receiving or has received stiripentol in the past 21 days prior to Screening.
- Currently taking carbamazepine, oxcarbamazepine, eslicarbazepine, phenobarbital, or phenytoin, or has taken any of these within the past 30 days.
- Positive result on tetrahydrocannabinol (THC) or cannabidiol (CBD) test at the Screening Visit.
- A clinically significant medical condition,that would interfere with study participation, collection of study data, or pose a risk to the subject.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02682927
Locations
Show 21 study locations
Sponsors and Collaborators
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Investigators
| Principal Investigator: | Joseph Sullivan, MD | University of California, San Francisco |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. |
| ClinicalTrials.gov Identifier: | NCT02682927 |
| Other Study ID Numbers: |
ZX008-1501 |
| First Posted: | February 17, 2016 Key Record Dates |
| Last Update Posted: | January 7, 2020 |
| Last Verified: | January 2020 |
Keywords provided by Zogenix, Inc. ( Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. ):
|
seizure tonic-atonic clonic |
epilepsy myoclonic encephalopathy |
Additional relevant MeSH terms:
|
Seizures Epilepsies, Myoclonic Epilepsy Syndrome Disease Pathologic Processes Neurologic Manifestations Nervous System Diseases Epilepsy, Generalized Brain Diseases |
Central Nervous System Diseases Epileptic Syndromes Fenfluramine Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Serotonin Agents Physiological Effects of Drugs |